论文部分内容阅读
目的探讨新辅助化疗方案治疗三阴乳腺癌的疗效。方法选取2009年1月～2013年1月在我院接受治疗的三阴乳腺癌患者88例作为研究对象,随机分为对照组与观察组,对照组采用AC(阿霉素+环磷酰胺)新辅助化疗方案,观察组采用ET(蒽环类+多西紫杉醇)新辅助化疗方案,对比两组患者的疗效、肿瘤标志物CA15-3转阴的疗程数以及并发症情况。结果 AC与ET组的新辅助化疗有效率分别为54.8%及80.5%,对比具有统计学意义(χ2=9.386,P=0.025),肿瘤标志物CA15-3转阴的疗程对比χ2=5.427,P=0.019,具有统计学意义;不良反应较轻,经对症处理均能完成化疗疗程。结论新辅助化疗方案对三阴乳腺癌疗效肯定,但仍有一定的局限性,其中以蒽环类联合紫杉醇类效果较好。
Objective To investigate the efficacy of neoadjuvant chemotherapy in the treatment of triple negative breast cancer. Methods Eighty-eight patients with triple-negative breast cancer who were treated in our hospital from January 2009 to January 2013 were randomly divided into the control group and the observation group. The control group was treated with AC (adriamycin + cyclophosphamide). In the neoadjuvant chemotherapy protocol, the observation group was treated with ET (anthracycline plus docetaxel) neoadjuvant chemotherapy. The efficacy of the two groups of patients, the number of tumor markers CA15-3 negative course of treatment, and complications were compared. Results The effective rates of neoadjuvant chemotherapy in the AC and ET groups were 54.8% and 80.5%, respectively. The contrast was statistically significant (χ2=9.386, P=0.025). The course of contrast of the tumor marker CA15-3 negative was χ2=5.427,P. = 0.019, with statistical significance; adverse reactions are mild, and symptomatic treatment can complete the course of chemotherapy. Conclusion The efficacy of neoadjuvant chemotherapy for triple-negative breast cancer is positive, but there are still some limitations. Among them, anthracycline combined with paclitaxel has a good effect.